<![CDATA[FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC]]>

RegulatoryapprovedNogapendekin AlfaPositive

AI Analysis

Summary

The FDA has expanded approval for nogapendekin alfa to treat BCG-unresponsive non-muscle invasive bladder cancer, supported by data from the phase 2/3 QUILT-3.032 trial.

Clinical Trial Data

Phase

2/3

Outcome Details

FDA expanded approval for nogapendekin alfa in BCG-unresponsive NMIBC

Importance:7/10

Sentiment:

0.70

FDA approvalexpanded indicationoncologybladder cancerNMIBCclinical trial data

Read the original article

Published by Cancer Network on October 14, 2026 3:25 PM

Read Original